Wells Fargo Maintains Equal-Weight on aTyr Pharma, Raises Price Target to $4
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Wells Fargo analyst Derek Archila maintains aTyr Pharma (NASDAQ:ATYR) with a Equal-Weight and raises the price target from $1 to $4.
Wells Fargo analyst Derek Archila maintains aTyr Pharma (NASDAQ:ATYR) with a Equal-Weight and raises the price target from $1 to $4.
